ARCHIVES

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

This article is from The Cancer Letter archive.

Vol. 28 No. 41 | November 8, 2002

Download PDF Visit The Full Archive

Related Articles

MSK Investigators Report Sialic Acid Test 95% Accurate; Negative Immunotherapy Results Told

June 13, 1980

City of Hope CEO Michael Friedman: Cancer Centers Must Adapt; “Not Losing Sleep” Over Sequestration

April 5, 2013

Nobel In Chemistry For Work Linking Carbon Atoms

October 8, 2010

“Sloppy” Cancer Control Grant Applications Turned Down At Twice NIH Disapproval Rate

November 7, 1975

NCI says SELECT study is close to full enrollment.

April 23, 2004

In Brief: Doug Ulman named CEO of Pelotonia

September 26, 2014